THZ1

Manufacturer	MedChem Express
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Amount	100 mg
Item no.	HY-80013-100mg
Targets	CDK
CASRN	1604810-83-4
eClass 6.1	30220300
eClass 9.0	32160605
Available
Product Description	THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression[1][2].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	566.05
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)\|Ethanol : 1.4 mg/mL (ultrasonic)
Manufacturers Target	CDK
Isoform	CDK12; CDK13; CDK7
Pathway	Cell Cycle/DNA Damage
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-80013-100mg-safety-datasheet.pdf